Lightship has entered a collaboration with Acclinate to boost access and engagement in clinical trials for populations which are underrepresented.

The companies will partner on solutions to boost trial access to diverse populations and people of colour. 

To design and offer trials that are easily accessible and provide increased choice to people in need, the alliance will combine Acclinate’s #NOWINCLUDED community and e-DICT engagement and predictive analytics platform with Lightship’s personalised approach.

This strategy is being leveraged to engage subjects in a neurology trial underway in the US for a top pharmaceutical firm.

Lightship CEO David MacMurchy said: “Removing common barriers to clinical trial participation such as geographic constraints or logistical concerns around travelling to a site, missing time from work or coordinating childcare, helps increase access to clinical research.

“Our partnership with Acclinate leverages their established, trusted community connections, digital platform and app with Lightship’s robust clinical trial infrastructure and commitment to meeting participants where they are to deliver their clinical trial.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Their partnership has so far resulted in close to 5,000 individuals getting a chance to gain access to the trial with a nearly 10% resultant engagement response rate.

Acclinate co-founder and CEO Delmonize Smith said: “Our #NOWINCLUDED community educates, engages, and empowers communities of colour to make informed decisions about their health, including opportunities to take part in clinical trials.

“Combined with our e-DICT predictive analytics tool, we help pharmaceutical companies and other health organisations present their clinical trials to diverse members who are most likely to participate.”